Evogene (NASDAQ: EVGN) reported Q2 EPS of ($1.06), $0.19 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $914 thousand versus the consensus estimate of $775 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.